Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?

Biotech giant Gilead Sciences, Inc. (GILD) has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 21.1% year to date against the industry’s decline of 4.7%. The stock has outperformed the sector and the S&P 500 Index in this timeframe.Gilead Outperforms Industry, Sector & S&P 500 IndexImage Source: Zacks Investment ResearchGilead Sciences is a dominant player in the HIV market with market-leading treatments. Its diverse portfolio also includes drugs for liver, hemat ...